Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald restated a hold rating and issued a $19.00 target price (up previously from $15.00) on shares of Omeros in a research note on Thursday, August 24th. Zacks Investment Research upgraded shares of Omeros from a sell rating to a hold rating in a research note on Wednesday, November 15th. Wedbush restated an outperform rating and issued a $47.00 target price on shares of Omeros in a research note on Tuesday, November 28th. Maxim Group reiterated a buy rating and set a $24.00 price objective on shares of Omeros in a research note on Monday, November 6th. Finally, Cowen lowered shares of Omeros from an outperform rating to a market perform rating in a research note on Thursday, November 2nd. Five analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $34.14.
Shares of Omeros (NASDAQ OMER) traded up $0.55 during trading on Thursday, reaching $19.56. 753,456 shares of the company were exchanged, compared to its average volume of 796,912. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74. Omeros has a 12-month low of $8.71 and a 12-month high of $27.09.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC boosted its holdings in shares of Omeros by 7.8% in the first quarter. Teachers Advisors LLC now owns 68,285 shares of the biopharmaceutical company’s stock valued at $1,032,000 after acquiring an additional 4,951 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Omeros by 5.1% in the first quarter. Vanguard Group Inc. now owns 1,731,391 shares of the biopharmaceutical company’s stock valued at $26,179,000 after acquiring an additional 83,868 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Omeros by 20.1% in the first quarter. Morgan Stanley now owns 199,087 shares of the biopharmaceutical company’s stock valued at $3,010,000 after acquiring an additional 33,285 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Omeros by 5.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 195,117 shares of the biopharmaceutical company’s stock valued at $2,951,000 after acquiring an additional 10,194 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Omeros by 7.8% during the first quarter. Bank of America Corp DE now owns 78,894 shares of the biopharmaceutical company’s stock worth $1,193,000 after buying an additional 5,736 shares in the last quarter. Hedge funds and other institutional investors own 49.85% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Omeros (OMER) Given a $30.00 Price Target at HC Wainwright” was first reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/12/15/omeros-omer-given-a-30-00-price-target-at-hc-wainwright.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
What are top analysts saying about Omeros? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Omeros and related companies.